Brief: Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations From Mgta-117 Clinical Trial And Other Program Highlights

Dianthus Therapeutics

16/05/2022 13:07

Magenta Therapeutics Inc  MGTA.O :
    * MAGENTA THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL
RESULTS,
EARLY CLINICAL OBSERVATIONS FROM MGTA-117 CLINICAL TRIAL AND
OTHER PROGRAM HIGHLIGHTS
    * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF
MARCH 31,
2022, WERE $156.6 MILLION
    * MAGENTA THERAPEUTICS- EXPECTS CASH, CASH EQUIVALENTS AND
MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND ITS CURRENT
OPERATIONAL PLAN INTO Q2 OF 2024
    * QTRLY LOSS PER SHARE $0.39
    * Q1 EARNINGS PER SHARE VIEW $-0.31 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw1v8BfFa 
Further company coverage:  MGTA.O